null

Advanced therapy medicinal products (ATMPs)

Share this page

Request your certificate of attendance
Other live channels you can watch

Welcome and Opening of the Biotech Atelier

Keynote lecture

Digital Health and Artificial Intelligence

Real-World Evidence (RWE) and HTA

Interview

Personalized Medicine: Recent Developments

Personalized Medicine: Biomarkers

Human Capital in “Corona Times” and beyond

The Life Science Funding in “Corona Times” and beyond

Digital Therapeutics

Biotechnology Innovation and Investment – Before, Now and Then

Innovations in the COVID-19 Era

Artificial Intelligence in the COVID-19 Era

Personalized Medicine: Biobanking and Population Genetics

Chief Patient Officer

Future of clinical trials, AI and data

Personalization, Pharmacogenetics and Pharmacogenomics

Innovation in Medicine – ATMPs

Clinical Trials

How Germany managed the coronavirus crisis

Personalized Psychiatry

Regulatory Challenges in the COVID Era

Medical Cannabis – the Wonder Substance

Hospital Exemption for ATMPs

Medical Devices in the Digital Health Era

COVID-19: the New Reality in Bulgaria and Worldwide

COVID-19 Diagnostic and Therapy, the Bulgarian Perspective

COVID-19 Diagnostics: Hear the Experts

Water and Biotechnologies

Plant Biotechnology: Beyond

Keynote

Fireside chat

Office hours

Keynote

Jury QnA and Awards

Keynotes – COVID-19

Healthcare and Pharma Dynamics, 2020

Precision Medicine’s Potential and Current Gaps

11 years ATMPs

ATMPs, patient’s perspective

ATMPs, logistics

ATMPs, Leveraging the Digital Supply Chain

IBM Solutions in Healthcare

The Supercomputers – modern accelerators of innovation in healthcare

Beyond healthcare system towards a health-tech ecosystem

3D Bioprinting? (CTI Biotech)

Big Data and AI in Digital Health

BDADH – GATE Institute – Research areas and application themes

BDADH – Session 2 opening

BDADH – Session 1 opening

BDADH – Detecting and characterizing complex variation in the human genome sequence that can affect brain function

BDADH – Non-invasive biomarker detection, identification, and computational modeling for neonatal health

BDADH – Leveraging AI and RWE Big Data to Develop Novel Multi-omic AI Diagnostic Test for Immuno-Oncology Therapy in Lung Cancer

BDADH – Q & A Session 1

BDADH – Session 2 opening

BDADH – Clinical aspects of dementia management and follow-up in Bulgaria and opportunities for digitalisation

BDADH – Digital twin modelling of patients with cognitive disorders

BDADH – Q & A Session 2

Healthtech and Biotech startup track

PBB – The future of plant agriculture

PBB – Will computational biology push the next breakthrough in plant biotechnology and breeding?

FCTAID – Welcome and opening

FCTAID – Setting the scene: Future of clinical trials – what it would be?

FCTAID – Clinical Research Landscape in Bulgaria – From Status Quo toward Status GO!

FCTAID – Clinical Trials market & Financial impact – Global overview

FCTAID – Scientific evidence based ethical assessment. Future objectives of national ethics committee.

FCTAID – Discussion

FCTAID – Break 1

FCTAID – The lack of data as an obstacle to the clinical trials development in CEE

FCTAID – Patient-centric software powering decentralised trials

FCTAID – Research transparency, public involvement and proportionality of ethical review

FCTAID – Activities of the Ethics Committee for Clinical Trials in Bulgaria to meet the challenges of the new regulatory requirements in the EU and to improve the environment for conducting clinical trials in Bulgaria

FCTAID – Decentralised clinical trials: moving from nicety to necessity

FCTAID – High level overview of several digital innovations and technologies that help advance healthcare research and clinical care

FCTAID – Q&A

FCTAID – Break 2

FCTAID – NIHR Clinical Research Network: the delivery arm of the NHS

FCTAID – How to embed research in a national health service

FCTAID – Clinical Trials in Bulgaria – Key Challenges

FCTAID – Sleep disorders and clinical trials: new challenges and perspectives

FCTAID – At a time of a global pandemic we recognize more than ever the need for clinical research- key note on the importance, benefits and socio-economic impact of clinical trials

FCTAID – Romanian clinical trials market – huge potential suffocated by lack of vision

FCTAID – The importance of clinical research in saving patient’s life – academy point of view

FCTAID – Break 3

FCTAID – Improved adverse event/medical error reporting

FCTAID – Discussion 2

FCTAID – Conclusions and closure

FCTAID – Using AI to generate Real World Evidence (RWE)

PPP – Welcome and Opening

PPP – Personalized Medicine – the New Reality in Medical School?

PPP – Moving from disease treatment to disease prevention – personalization is the key

PPP – Implementation of Pharmacogenetic testing: what are the priorities?

PPP – Pharmacogenetics in oncology clinical practice

PPP – Break 1

PPP – Progressing a data driven healthcare system

PPP – Donor-derived cell-free DNA testing in organ transplantation: a value proposition

PPP – Enhancing Precision Medicine and Pharmacogenetics through Clinical Mass Spectrometry Platform

PPP – Rational Cancer Therapy

PPP – Closing discussion and remarks

ATMPs – Opening

ATMPs – Introduction

ATMPs – EU ATMP development landscape and outlook

ATMPs – ATMP update and Regulatory Strategy

ATMPs – Q&A session

ATMPs – Break 1

ATMPs – Nonclinical Challenges and Cases with ATMPs

ATMPs – CMC Challenges and case studies with ATMPs

ATMPs – Q&A session 2

ATMPs – Break 2

ATMPs – The ATMP post approval path – patient and market access

ATMPs – Riding the clinical trial rollercoaster – a patient’s perspective

ATMPs – Q&A session 3

Featured Posters 1D

Featured Posters 3D

Featured Posters 4D

FCTAID – Patient First: changing the clinical trials paradigm

IRI – Research infrastructures: Why do we need them?

IRI – Covid – what can infrastructures do going forward

IRI – Infrastructures Role in developing Personalized Health

Potable water and biotechnologies

Topic for the near future: Water microbiome

Wastewater and Biotechnologies

The future of the water sector: Matching needs and technologies

Welcome and Opening

Potable Water and Biotechnologies

Wastewater and Biotechnologies

Water and Health

Lunch and networking time

The Future of the Water Sector – Matching Needs and Technologies

Closing remarks

Networking Hour

Welcome and Opening

Genomics and data to support personalised medicine (incl. registers/biobanks, biomarkers assessment)

Discussion panel with Q&A from the audience

Adoption of personalised medicine (incl. patient centricity, health technology assessment, regulations)

Discussion panel with Q&A from the audience

Comfort break

Personalised medicine – what the future brings?

Discussion panel with Q&A from the audience

Conclusions and closure

Welcome and Opening of the Biotech Atelier

Movement Health 2030: the Future of Healthcare

The Innovative Health Initiative – Europe’s new public private partnership in health

The Microbiome and Nutrigenetics

Break

Non-invasive Prenatal and Neonatal Testing

Lifestyle and Health Advances

Topic – TBD

Psychiatry: Pharmacogenetics and Personalised Practices

Assisted reproductive technology (ART)

Social freezing not cost effective to the society

Break

Problems with Using Polygenic Scores to Select Embryos

Bye Bye Paper

Where are we now? Did CSV keep its promises?

Advances in Diagnosis and Management of ATTR amyloid cardiomyopathy

Discussion

The Value of Patient Centricity – Why the Patient Voice is Essential

Interview

Digital Health: Supporting Health Through Technologies

Digital Solutions to Healthcare Problems

Break

Break

Break

AI for Alzheimer Disease

HIV – The neglected pandemic

Quality Assurance in a Molecualr Food Testing laboratory (an overview)

Human Genetics in Favor of Reliable Diagnostics

Keynote lecture

The Role of biomarkers in Personalised Medicine

Precision medicine in daily routine, face reality

Impact of access to biomarker test on the patient pathway

Liquid biopsy – TBC

Advantages of automated and digital Tissue Engineering and 3D cell cultivation

Panel 1

Panel 2

Panel 3

Data Platforms for Digital Health

DTx – AI as a medical device

DTx – DTx in Cancer Treatment

DTx – DTx Funding

DTx – DTx Innovations

DTx – Health Equality Through Innovation

DTx – DTx in Neuroscience

Comfort Break

Panel Discussion

The Potential of Gene Therapy for People with Rare Genetic Disorders

Movement Health 2030 – Central and Eastern Europe (CEE)

Movement Health 2030 – Bulgaria

Wastewater and Antimicrobial Resistance

Keynote lecture 2

Closing Remarks

The Concept and Value of Patient Advocacy

My Stage IV Cancer Journey… And what helped me through it

Towards a patient-centred approach in cancer care

The value of patient advocacy in the field of oncology

Prevention in Action – Cervical Cancer

Cancer Registers – first steps: Armenia, Brazil and Kenya

Pancreatic Cancer – increasing pancreatic cancer awareness

Pain management – pancreatic cancer

Inspire2Live and International Agency for Research in Cancer (IARC) partnership and collaboration

Dicsussion and Conclusion

Personalised Medicine and Patient Advocacy

The Intersection of a Science Background and Patient Advocacy: How I Became a Better Advocate

Don’t let Cancer become the Forgotten “C” in the Fight against COVID-19

COVID-19 vaccination for Cancer Patients

How to fund your life science/biotech startup with non-dilutive funding

Menopause and Employment – the Law

Success Stories

AHT – HIV – the Neglected Pandemic

AHT – Comfort Break

AHT – Keynote lecture 1

AHT – Human Genetics in Favor of Reliable Diagnostics

AHT – Keynote lecture 2

AHT – Wastewater and Antimicrobial Resistance

AHT – Keynote lecture 3

AHT – Closing Remarks

PM – The Microbiome and Nutrigenetics

PM – Comfort break

PM – Non-invasive Prenatal and Neonatal Testing

PM – Lifestyle and Health Advances

PM – Kip Olmstead Keynote

PM – Psychiatry: Pharmacogenetics and Personalised Practices

PM – Daniel Dowd Keynote

PM – Neurology: precision medicine and management

PM – Closing Remarks

AHT – Opening / Introduction

TBD

CSV – Where are we now

CSV – CSV and CSA

CSV – Bye Bye Paper

CSV – Lunch break

CSV – Validating AI/ML Solutions

CSV – Coffee break

CSV – Panel discussion

CSV – CSV and Best Practices

GATE – Welcome

GATE – GATE Flagship project on Alzheimer

CSV and CSA

Validating AI/ML Solutions

Panel 3

Personalised Medicine – building bridges among patients, researchers, decision makers & industry

GATE – Data platform UK

GATE – GATE Data platform

GATE – Privacy-preserving AI-based diagnostic tools for Alzheimer disease

GATE – Discussion

Welcome and Opening of the Biotech Atelier

Keynote lecture

Digital Health and Artificial Intelligence

Real-World Evidence (RWE) and HTA

Interview

Personalized Medicine: Recent Developments

Personalized Medicine: Biomarkers

Human Capital in “Corona Times” and beyond

The Life Science Funding in “Corona Times” and beyond

Digital Therapeutics

Biotechnology Innovation and Investment – Before, Now and Then

Innovations in the COVID-19 Era

Artificial Intelligence in the COVID-19 Era

Personalized Medicine: Biobanking and Population Genetics

Chief Patient Officer

Future of clinical trials, AI and data

Personalization, Pharmacogenetics and Pharmacogenomics

Innovation in Medicine – ATMPs

Clinical Trials

How Germany managed the coronavirus crisis

Personalized Psychiatry

Regulatory Challenges in the COVID Era

Medical Cannabis – the Wonder Substance

Hospital Exemption for ATMPs

Medical Devices in the Digital Health Era

COVID-19: the New Reality in Bulgaria and Worldwide

COVID-19 Diagnostic and Therapy, the Bulgarian Perspective

COVID-19 Diagnostics: Hear the Experts

Water and Biotechnologies

Plant Biotechnology: Beyond

Keynote

Fireside chat

Office hours

Keynote

Jury QnA and Awards

Keynotes – COVID-19

Healthcare and Pharma Dynamics, 2020

Precision Medicine’s Potential and Current Gaps

11 years ATMPs

ATMPs, patient’s perspective

ATMPs, logistics

ATMPs, Leveraging the Digital Supply Chain

IBM Solutions in Healthcare

The Supercomputers – modern accelerators of innovation in healthcare

Beyond healthcare system towards a health-tech ecosystem

3D Bioprinting? (CTI Biotech)

Big Data and AI in Digital Health

BDADH – GATE Institute – Research areas and application themes

BDADH – Session 2 opening

BDADH – Session 1 opening

BDADH – Detecting and characterizing complex variation in the human genome sequence that can affect brain function

BDADH – Non-invasive biomarker detection, identification, and computational modeling for neonatal health

BDADH – Leveraging AI and RWE Big Data to Develop Novel Multi-omic AI Diagnostic Test for Immuno-Oncology Therapy in Lung Cancer

BDADH – Q & A Session 1

BDADH – Session 2 opening

BDADH – Clinical aspects of dementia management and follow-up in Bulgaria and opportunities for digitalisation

BDADH – Digital twin modelling of patients with cognitive disorders

BDADH – Q & A Session 2

Healthtech and Biotech startup track

PBB – The future of plant agriculture

PBB – Will computational biology push the next breakthrough in plant biotechnology and breeding?

FCTAID – Welcome and opening

FCTAID – Setting the scene: Future of clinical trials – what it would be?

FCTAID – Clinical Research Landscape in Bulgaria – From Status Quo toward Status GO!

FCTAID – Clinical Trials market & Financial impact – Global overview

FCTAID – Scientific evidence based ethical assessment. Future objectives of national ethics committee.

FCTAID – Discussion

FCTAID – Break 1

FCTAID – The lack of data as an obstacle to the clinical trials development in CEE

FCTAID – Patient-centric software powering decentralised trials

FCTAID – Research transparency, public involvement and proportionality of ethical review

FCTAID – Activities of the Ethics Committee for Clinical Trials in Bulgaria to meet the challenges of the new regulatory requirements in the EU and to improve the environment for conducting clinical trials in Bulgaria

FCTAID – Decentralised clinical trials: moving from nicety to necessity

FCTAID – High level overview of several digital innovations and technologies that help advance healthcare research and clinical care

FCTAID – Q&A

FCTAID – Break 2

FCTAID – NIHR Clinical Research Network: the delivery arm of the NHS

FCTAID – How to embed research in a national health service

FCTAID – Clinical Trials in Bulgaria – Key Challenges

FCTAID – Sleep disorders and clinical trials: new challenges and perspectives

FCTAID – At a time of a global pandemic we recognize more than ever the need for clinical research- key note on the importance, benefits and socio-economic impact of clinical trials

FCTAID – Romanian clinical trials market – huge potential suffocated by lack of vision

FCTAID – The importance of clinical research in saving patient’s life – academy point of view

FCTAID – Break 3

FCTAID – Improved adverse event/medical error reporting

FCTAID – Discussion 2

FCTAID – Conclusions and closure

FCTAID – Using AI to generate Real World Evidence (RWE)

PPP – Welcome and Opening

PPP – Personalized Medicine – the New Reality in Medical School?

PPP – Moving from disease treatment to disease prevention – personalization is the key

PPP – Implementation of Pharmacogenetic testing: what are the priorities?

PPP – Pharmacogenetics in oncology clinical practice

PPP – Break 1

PPP – Progressing a data driven healthcare system

PPP – Donor-derived cell-free DNA testing in organ transplantation: a value proposition

PPP – Enhancing Precision Medicine and Pharmacogenetics through Clinical Mass Spectrometry Platform

PPP – Rational Cancer Therapy

PPP – Closing discussion and remarks

ATMPs – Opening

ATMPs – Introduction

ATMPs – EU ATMP development landscape and outlook

ATMPs – ATMP update and Regulatory Strategy

ATMPs – Q&A session

ATMPs – Break 1

ATMPs – Nonclinical Challenges and Cases with ATMPs

ATMPs – CMC Challenges and case studies with ATMPs

ATMPs – Q&A session 2

ATMPs – Break 2

ATMPs – The ATMP post approval path – patient and market access

ATMPs – Riding the clinical trial rollercoaster – a patient’s perspective

ATMPs – Q&A session 3

Featured Posters 1D

Featured Posters 3D

Featured Posters 4D

FCTAID – Patient First: changing the clinical trials paradigm

IRI – Research infrastructures: Why do we need them?

IRI – Covid – what can infrastructures do going forward

IRI – Infrastructures Role in developing Personalized Health

Potable water and biotechnologies

Topic for the near future: Water microbiome

Wastewater and Biotechnologies

The future of the water sector: Matching needs and technologies

Welcome and Opening

Potable Water and Biotechnologies

Wastewater and Biotechnologies

Water and Health

Lunch and networking time

The Future of the Water Sector – Matching Needs and Technologies

Closing remarks

Networking Hour

Welcome and Opening

Genomics and data to support personalised medicine (incl. registers/biobanks, biomarkers assessment)

Discussion panel with Q&A from the audience

Adoption of personalised medicine (incl. patient centricity, health technology assessment, regulations)

Discussion panel with Q&A from the audience

Comfort break

Personalised medicine – what the future brings?

Discussion panel with Q&A from the audience

Conclusions and closure

Welcome and Opening of the Biotech Atelier

Movement Health 2030: the Future of Healthcare

The Innovative Health Initiative – Europe’s new public private partnership in health

The Microbiome and Nutrigenetics

Break

Non-invasive Prenatal and Neonatal Testing

Lifestyle and Health Advances

Topic – TBD

Psychiatry: Pharmacogenetics and Personalised Practices

Assisted reproductive technology (ART)

Social freezing not cost effective to the society

Break

Problems with Using Polygenic Scores to Select Embryos

Bye Bye Paper

Where are we now? Did CSV keep its promises?

Advances in Diagnosis and Management of ATTR amyloid cardiomyopathy

Discussion

The Value of Patient Centricity – Why the Patient Voice is Essential

Interview

Digital Health: Supporting Health Through Technologies

Digital Solutions to Healthcare Problems

Break

Break

Break

AI for Alzheimer Disease

HIV – The neglected pandemic

Quality Assurance in a Molecualr Food Testing laboratory (an overview)

Human Genetics in Favor of Reliable Diagnostics

Keynote lecture

The Role of biomarkers in Personalised Medicine

Precision medicine in daily routine, face reality

Impact of access to biomarker test on the patient pathway

Liquid biopsy – TBC

Advantages of automated and digital Tissue Engineering and 3D cell cultivation

Panel 1

Panel 2

Panel 3

Data Platforms for Digital Health

DTx – AI as a medical device

DTx – DTx in Cancer Treatment

DTx – DTx Funding

DTx – DTx Innovations

DTx – Health Equality Through Innovation

DTx – DTx in Neuroscience

Comfort Break

Panel Discussion

The Potential of Gene Therapy for People with Rare Genetic Disorders

Movement Health 2030 – Central and Eastern Europe (CEE)

Movement Health 2030 – Bulgaria

Wastewater and Antimicrobial Resistance

Keynote lecture 2

Closing Remarks

The Concept and Value of Patient Advocacy

My Stage IV Cancer Journey… And what helped me through it

Towards a patient-centred approach in cancer care

The value of patient advocacy in the field of oncology

Prevention in Action – Cervical Cancer

Cancer Registers – first steps: Armenia, Brazil and Kenya

Pancreatic Cancer – increasing pancreatic cancer awareness

Pain management – pancreatic cancer

Inspire2Live and International Agency for Research in Cancer (IARC) partnership and collaboration

Dicsussion and Conclusion

Personalised Medicine and Patient Advocacy

The Intersection of a Science Background and Patient Advocacy: How I Became a Better Advocate

Don’t let Cancer become the Forgotten “C” in the Fight against COVID-19

COVID-19 vaccination for Cancer Patients

How to fund your life science/biotech startup with non-dilutive funding

Menopause and Employment – the Law

Success Stories

AHT – HIV – the Neglected Pandemic

AHT – Comfort Break

AHT – Keynote lecture 1

AHT – Human Genetics in Favor of Reliable Diagnostics

AHT – Keynote lecture 2

AHT – Wastewater and Antimicrobial Resistance

AHT – Keynote lecture 3

AHT – Closing Remarks

PM – The Microbiome and Nutrigenetics

PM – Comfort break

PM – Non-invasive Prenatal and Neonatal Testing

PM – Lifestyle and Health Advances

PM – Kip Olmstead Keynote

PM – Psychiatry: Pharmacogenetics and Personalised Practices

PM – Daniel Dowd Keynote

PM – Neurology: precision medicine and management

PM – Closing Remarks

AHT – Opening / Introduction

TBD

CSV – Where are we now

CSV – CSV and CSA

CSV – Bye Bye Paper

CSV – Lunch break

CSV – Validating AI/ML Solutions

CSV – Coffee break

CSV – Panel discussion

CSV – CSV and Best Practices

GATE – Welcome

GATE – GATE Flagship project on Alzheimer

CSV and CSA

Validating AI/ML Solutions

Panel 3

Personalised Medicine – building bridges among patients, researchers, decision makers & industry

GATE – Data platform UK

GATE – GATE Data platform

GATE – Privacy-preserving AI-based diagnostic tools for Alzheimer disease

GATE – Discussion

Menu
Skip to content